Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech ...

The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals from its miniprotein radioconjugate platform.

Another Bay State biotech has filed plans to begin the IPO process, stoking predictions that a resurgence of the public ...

Akston Biosciences Corp., pet medicines company, has filed paperwork with the U.S. Securities and Exchange Commission to begin the initial public offering process.

The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...

Lumexa Imaging hauled in $462.5 million during its initial public offering, far exceeding the $200 million the outpatient diagnostic services provider had earlier planned. | Lumexa Imaging hauled in ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

The IPO market for new technology listings picked up in 2025. So far this year, at least 23 U.S.-based companies have listed above $1 billion in value, compared to nine in 2024, per an analysis of ...

Jyong Biotech aims to raise $18.8 million in a US IPO. The company develops plant-based treatments for urinary diseases but faces FDA efficacy doubts and high legal cost exposure. Financially, Jyong ...